CE Marking and ARCH clinical trial data position the Liverty™ TIPS Stent Graft to expand treatment options for patients with advanced liver disease

FRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced application of CE Mark for the Liverty™ TIPS Stent Graft, delivering innovation to portal hypertension care across the European Union. Designed to expand treatment options for patients with cirrhosis and complications of portal hypertension, our next‑generation, adjustable‑diameter device represents the latest advancement by BD in interventional therapies addressing complex liver disease. Safety and effectiveness data from the pivotal ARCH clinical trial evaluating the Liverty™ TIPS Stent Graft will be presented for the first time at the Society of Interventional Radiology (SIR) Annual Scientific Meeting on April 12, 2026.